Emerald Health Therapeutics, Inc. (EMHTF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Emerald Health Therapeutics, Inc. (EMHTF) stock?
Emerald Health Therapeutics, Inc. (EMHTF) no longer trades on public markets. The figures below are historical and are not a current quote.
Beta 0.63: the stock has moved about 37% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Emerald Health Therapeutics, Inc. (EMHTF). Emerald Health Therapeutics, Inc. focuses on the production, distribution, and sale of recreational and medical cannabis in Canada. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for EMHTF: EMHTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EMHTF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
EMHTF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Emerald Health Therapeutics, Inc. (EMHTF) Healthcare & Pipeline Overview
Emerald Health Therapeutics, Inc. is a Canadian cannabis company involved in the production, distribution, and sale of recreational and medical cannabis products. Operating as a subsidiary of Skye Bioscience, Inc., Emerald Health offers a range of cannabis products, facing strong competition in the evolving Canadian cannabis market.
What Is the Investment Thesis for EMHTF?
Investing in Emerald Health Therapeutics, Inc. (EMHTF) presents a high-risk, high-reward scenario. The company's negative profit margin of -411.9% and gross margin of -66.7% indicate significant financial challenges. EMHTF operates in the competitive Canadian cannabis market, where profitability has been elusive for many players. A potential growth catalyst lies in the expansion of its product lines and market reach within Canada. However, investors should closely monitor EMHTF's financial performance and its ability to achieve sustainable profitability. The company's status as a subsidiary of Skye Bioscience, Inc. adds another layer of complexity, as its strategic direction may be influenced by its parent company. Given the current financial metrics and competitive landscape, EMHTF requires a turnaround strategy to deliver value to investors.
Based on FMP financials and quantitative analysis
EMHTF Key Highlights
Negative Profit Margin: Emerald Health Therapeutics has a profit margin of -411.9%, indicating substantial losses.
- Negative Gross Margin: The company's gross margin is -66.7%, reflecting challenges in cost management and pricing.
- P/E Ratio: Emerald Health Therapeutics has a P/E ratio of -0.27, signaling that the company is currently unprofitable.
- Subsidiary Status: Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc. since November 10, 2022.
- Beta: The company has a beta of 0.63, suggesting lower volatility compared to the overall market.
Who Are EMHTF's Competitors?
EMHTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CNPOF RIV Capital Inc. | $0.08 | 0.00% | $11.0M | — |
| HBCNF HealthBeacon plc | $0.50 | +2269.67% | $8.44M | — |
| IMUN Immune Therapeutics, Inc. | $0.09 | -7.00% | $7.78M | — |
| MKKGY Merck KGaA | $30.59 | +0.33% | $66.5B | 499-signal |
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| HLN Haleon plc | $9.22 | -0.11% | $40.6B | 775-pillar |
| SDZNY Sandoz Group AG | $81.08 | -2.68% | $35.1B | 519-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are EMHTF's Key Strengths?
Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Subsidiary of Skye Bioscience, Inc., providing potential access to resources and expertise.
What Are EMHTF's Weaknesses?
Negative profit and gross margins indicating financial struggles.
- Dependence on the Canadian cannabis market.
- Intense competition from other licensed producers.
- Operating as a subsidiary may limit strategic autonomy.
What Could Drive EMHTF Stock Higher?
Potential regulatory changes in the Canadian cannabis market that could benefit licensed producers.
- Expansion of product lines to include new and innovative cannabis products.
- Geographic expansion within Canada to reach new markets.
- Focus on the higher-margin medical cannabis market.
- Strategic partnerships and acquisitions to expand capabilities.
What Are the Key Risks for EMHTF?
Negative return on equity (-74.4%) — the business is not currently generating profit on shareholder capital.
- Oversupply and price compression in the Canadian cannabis market.
- Changing regulations and consumer preferences.
- Competition from illicit cannabis producers.
- Potential for further financial losses due to negative profit and gross margins.
- Dependence on the Canadian cannabis market.
What Are the Growth Opportunities for EMHTF?
- Expansion of Product Lines: Emerald Health can expand its product offerings to include new and innovative cannabis products, such as edibles, concentrates, and topicals. The market for these products is growing rapidly, driven by consumer demand for alternative consumption methods. By introducing new products, Emerald Health can attract new customers and increase its market share. The timeline for this growth opportunity is immediate, as the company can begin developing and launching new products in the near term. Success depends on effective product development and marketing strategies.
- Geographic Expansion within Canada: Emerald Health can expand its distribution network to reach new markets within Canada. This could involve partnering with retailers in provinces where the company currently has limited presence or establishing its own retail locations. Geographic expansion would allow Emerald Health to increase its sales volume and diversify its revenue streams. The timeline for this growth opportunity is medium-term, as it may take time to secure partnerships and establish new retail locations. Success depends on effective market research and strategic partnerships.
- Focus on Medical Cannabis Market: Emerald Health can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This could involve developing cannabis-based pharmaceuticals or partnering with healthcare providers to offer cannabis-based treatments. The medical cannabis market is growing rapidly, driven by increasing awareness of the therapeutic benefits of cannabis. The timeline for this growth opportunity is long-term, as it may take time to develop new pharmaceuticals and secure regulatory approvals. Success depends on scientific research and clinical trials.
- Strategic Partnerships and Acquisitions: Emerald Health can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other cannabis companies, technology companies, or healthcare providers. Strategic partnerships and acquisitions can provide access to new technologies, markets, and expertise. The timeline for this growth opportunity is ongoing, as the company can continuously explore potential partnerships and acquisitions. Success depends on effective due diligence and integration.
- Development of Proprietary Cannabis Strains: Emerald Health can invest in research and development to develop proprietary cannabis strains with unique characteristics, such as higher potency, unique flavor profiles, or specific therapeutic benefits. Proprietary strains can provide a competitive advantage and allow the company to differentiate its products. The timeline for this growth opportunity is long-term, as it may take time to develop and stabilize new strains. Success depends on scientific expertise and effective breeding programs.
What Are EMHTF's Competitive Advantages?
- Brand recognition through SYNC Wellness, fuse, Emerald, and Souvenir brands.
- Established distribution network in the Canadian cannabis market.
- Proprietary formulations for oral sprays and nano emulsion shots.
- Access to a range of cannabis strains and product formats.
What Does EMHTF Do?
Emerald Health Therapeutics, Inc. was initially founded as T-Bird Pharma Inc. before rebranding in June 2015 to reflect its focus on the burgeoning cannabis industry. Headquartered in Vancouver, Canada, the company cultivates, processes, and distributes a variety of cannabis products, including dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products. These products are marketed under several brands, including SYNC Wellness, fuse, Emerald, and Souvenir. Emerald Health aims to cater to both the recreational and medical cannabis markets in Canada. However, as of November 10, 2022, Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc., marking a significant shift in its corporate structure. The company's evolution reflects the dynamic nature of the cannabis industry, with Emerald Health adapting its strategy to navigate regulatory changes and evolving consumer preferences. Its product portfolio is designed to appeal to a broad spectrum of cannabis users, from those seeking traditional dried flower to those preferring more innovative consumption methods like oral sprays and nano emulsion shots.
What Products and Services Does EMHTF Offer?
- Produces dried cannabis strains for recreational and medical use.
- Manufactures pre-rolled cannabis products for convenient consumption.
- Develops and sells oral sprays containing cannabis extracts.
- Offers nano emulsion shots for rapid cannabis absorption.
- Produces cannabis oil products for various applications.
- Markets its products under the SYNC Wellness, fuse, Emerald, and Souvenir brands.
- Distributes cannabis products through various channels in Canada.
How Does EMHTF Make Money?
- Cultivates and processes cannabis plants.
- Manufactures a range of cannabis products.
- Distributes and sells products through retail channels and partnerships.
- Generates revenue from the sale of cannabis products to recreational and medical consumers.
What Industry Does EMHTF Operate In?
Emerald Health Therapeutics operates within the Canadian cannabis industry, which has experienced significant growth since legalization but also faces challenges such as oversupply, regulatory hurdles, and intense competition. The market includes both recreational and medical cannabis segments, with evolving consumer preferences for different product formats. Key competitors include other licensed producers who are vying for market share. Emerald Health's success depends on its ability to differentiate its products, manage costs effectively, and navigate the complex regulatory landscape. The Canadian cannabis market is projected to continue growing, driven by increasing consumer acceptance and the development of new products and distribution channels.
Who Are EMHTF's Key Customers?
- Recreational cannabis consumers in Canada.
- Medical cannabis patients with prescriptions.
- Retail partners who sell Emerald Health's products.
- Wholesale distributors of cannabis products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 40 |
| 2026-08-24 | 40 |
| 2026-08-25 | 40 |
| 2026-08-26 | 40 |
What changed?
The score has stayed at 40.
Over the same 3 days the stock moved +0.0%.
Company Profile
Emerald Health Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. EMHTF has traded publicly since 2015.
Key Financial Metrics
Return on equity for Emerald Health Therapeutics, Inc. stands at -74.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -97.5%, showing how much profit it generates from its asset base. A current ratio of 3.08 indicates the company holds enough short-term assets to cover its near-term obligations.
EMHTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Subsidiary of Skye Bioscience, Inc., providing potential access to resources and expertise.
Bear Case
- Negative profit and gross margins indicating financial struggles.
- Dependence on the Canadian cannabis market.
- Intense competition from other licensed producers.
- Operating as a subsidiary may limit strategic autonomy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EMHTF Latest News
-
The Week In Cannabis: Stocks Up, Many Earnings Reports, A New ETF, And More
· Aug 28, 2020
-
Cannabis Stock Gainers And Losers From July 16, 2020
· Jul 16, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
EMHTF OTC Market Information
The OTC Other tier, where EMHTF trades, represents the lowest tier of the OTC market. Companies in this tier often face challenges in meeting minimum financial standards required for higher exchanges like NYSE or NASDAQ. These companies may be experiencing financial distress, be in early stages of development, or have chosen to remain private but still allow trading of their securities. Investing in companies on the OTC Other tier carries significant risks due to the lack of stringent listing requirements and oversight compared to major exchanges.
- OTC Tier: OTC Other
- Limited Liquidity: Low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Unknown disclosure status raises concerns about the availability of financial information.
- Financial Distress: The company's negative profit and gross margins suggest potential financial challenges.
- Regulatory Risks: OTC-listed companies are subject to less regulatory oversight compared to major exchanges.
- Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Verify the availability of financial reports and other relevant information.
- Assess the company's financial health and operational performance.
- Evaluate the company's management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volumes and bid-ask spreads.
- Consult with a financial advisor before making any investment decisions.
- Operation as a subsidiary of Skye Bioscience, Inc.
- Established brands such as SYNC Wellness and Emerald.
- Distribution network within the Canadian cannabis market.
- Engagement in the regulated cannabis industry in Canada.
Common Questions About EMHTF (Healthcare)
What happened to Emerald Health Therapeutics, Inc. (EMHTF) stock?
Emerald Health Therapeutics, Inc. (EMHTF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy EMHTF shares?
No. EMHTF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for EMHTF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EMHTF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Emerald Health Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Emerald Health Therapeutics, Inc. do?
Emerald Health Therapeutics, Inc. is a Canadian cannabis company involved in the production, distribution, and sale of recreational and medical cannabis products.
What do analysts say about EMHTF stock?
As of 2026-03-18, formal analyst ratings for Emerald Health Therapeutics (EMHTF) are limited, likely due to its OTC listing and financial performance. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability.
What are the main risks for EMHTF?
The main risks for Emerald Health Therapeutics include the oversupply and price compression in the Canadian cannabis market, which can negatively impact revenue and profitability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or less reliable than data from major exchanges.